Advancing Precision Medicine: Precigen Secures $30 Million in Funding

We are thrilled to announce that Precigen (Nasdaq: PGEN) has successfully raised $30 million in a recent funding round, marking a significant milestone in our mission to revolutionize medicine through precision technology. As a dedicated discovery and clinical stage biopharmaceutical company, Precigen is at the forefront of advancing the next generation of gene and cell therapies targeted at some of the most urgent and intractable diseases in the fields of immuno-oncology, autoimmune disorders, and infectious diseases. This funding will be instrumental in accelerating our innovative efforts to develop affordable biotherapeutics that provide meaningful solutions to patients in need. Leveraging our unique technologies, we are committed to advancing a robust pipeline of preclinical and clinical programs that promise to deliver well-differentiated therapies with the potential for clinical proof-of-concept and commercialization. The capital raised will facilitate our ongoing research, enhance our clinical trials, and strengthen our position as an innovation engine in the biopharmaceutical landscape. As we embark on this exciting journey, we express our gratitude to our investors for their support, which empowers us to drive forward with our vision of transforming patient care through advanced gene and cell therapies. We look forward to sharing our progress as we continue to push the boundaries of precision medicine.